This is a Phase II, multicenter, randomized, placebo-controlled, double-blind study to
evaluate the safety and efficacy of MOXR0916 in combination with atezolizumab versus placebo
and atezolizumab in participants with locally advanced or metastatic urothelial carcinoma
(UC) who have not received prior systemic therapy in the locally advanced/metastatic setting
and who are ineligible to receive cisplatin-based therapy.